Acrivon Therapeutics, Inc.

Develops precision cancer therapies by matching patients to drugs using its proteomics platform.

ACRV | NDAQ

Overview

Corporate Details

ISIN(s):: US0048901096
LEI:
Country:: United States of America
Address:: 480 ARSENAL WAY, SUITE 100, 2472 WATERTOWN
Website:: https://acrivon.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology. The company leverages its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to develop targeted cancer therapies. The AP3 platform utilizes phosphoproteomics to analyze the biologic drivers of a patient's cancer, enabling the creation of predictive 'OncoSignature' tests. This method is designed to match drug candidates with patients whose tumors are most likely to respond, aiming to improve therapeutic outcomes beyond what is achievable with genomics. Acrivon's pipeline is led by ACR-368, a selective kinase inhibitor in Phase 2 clinical trials for various solid tumors. The company also advances its internally developed programs and seeks strategic partnerships to apply its AP3 platform to co-develop predictive tests for external drug candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Acrivon Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Acrivon Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Acrivon Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
NFL Biosciences Develops botanical drug candidates to treat smoking and alcohol addictions.	France	ALNFL
NGS Group Nordic staffing & recruitment for healthcare, education, and social services sectors.	Sweden	NGS
Nihon M&A Center Holdings Inc. M&A advisory firm specializing in brokerage and consulting for Japanese SMEs, including cross-border deals.	Japan	2127
Noile-Immune Biotech Inc. Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.	Japan	4893
NRGene Technologies Ltd. AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.	Israel	NRGN
Nuvectis Pharma, Inc. Clinical-stage biopharma developing precision medicines for serious oncological conditions.	United States of America	NVCT
Nykode Therapeutics ASA Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.	Norway	NYKD
Ocugen, Inc. Develops gene/cell therapies and vaccines, specializing in blindness and public health.	United States of America	OCGN
Oculis Holding AG Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.	Switzerland	OCS
OKYO Pharma Ltd Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.	United States of America	OKYO